Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joe Osaben

Pain Medicine Rockford, IL Doctor of Osteopathy

NPI 1821026147 CMS profile 1155448

6451 E Riverside Blvd, Suite 103, Rockford, IL 61114

Open in the dashboard

General payments

$469

24 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joe Osaben of Rockford, IL is reported in the CMS Open Payments database as having received $469 across 24 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 23rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75 3
2024 General $56 3
2023 General $79 4
2022 General $62 3
2021 General $19 1
2020 General $74 4
2019 General $104 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joe Osaben
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Joe Osaben were reported at $75. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year Joe Osaben Pain Medicine median Middle half National median
2019 $104 $506 $144–$1,566 $163
2020 $74 $315 $96–$934 $114
2021 $19 $452 $134–$1,237 $132
2022 $62 $475 $124–$1,407 $149
2023 $79 $480 $136–$1,384 $160
2024 $56 $521 $164–$1,511 $164
2025 $75 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Avanos Medical $249 12 payments
  2. Orthogenrx Inc. $160 9 payments
  3. Fidia Pharma USA Inc. $38 2 payments
  4. Acella Pharmaceuticals, LLC $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $469 24 payments
Products named General payments · program years 2019–2025
  1. GENVISC 850 SODIUM HYALURONATE Pain Management $227 11 payments
  2. GenVisc 850 $141 8 payments
  3. HYMOVIS $38 2 payments
  4. TRIVISC SODIUM HYALURONATE Pain Management $22 1 payment
  5. TRILURON $22 1 payment
  6. NP Thyroid $22 1 payment
  7. TriVisc sodium hyaluronate Osteoarthritis $19 1 payment
  8. GenVisc 850 sodium hyaluronate Osteoarthritis $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

72

Median for Pain Management: 951

Drug cost

$26,246

Median for Pain Management: $26,034

Branded share of claims

51.4%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 12 $20,452
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 12 $4,174
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $678
Tramadol Hcl Generic 23 $632
Oxycodone Hcl Generic 12 $311

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$247,627

Of which drugs: $80,510

Medicare patients

124

Average age 74

Services billed

21,803

61 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 27%
Chronic kidney disease 24%
Heart failure 20%
Ischemic heart disease 19%
Atrial fibrillation 15%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg J7320 Office 93 17,986 $74,656
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 55 1,004 $275

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record